Category: Markets
Published: 2026-06-30T16:03:11.000Z
The FDA has approved Viridian Therapeutics' drug Lumvoa for thyroid eye disease, positioning it as a strong competitor to Amgen's Tepezza. Analysts believe Lumvoa's shorter infusion time, fewer infusions, and broader label covering both active and chronic thyroid eye disease give it a competitive advantage. While Lumvoa's pricing is similar to Tepezza, analysts project significant revenue growth by 2035 and Viridian is also developing an experimental subcutaneous treatment for chronic thyroid eye disease.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.